Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 538 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05545384RecruitingPhase 3
Immediate vs delayed azathioprine or rituximab for children with anti-MOG attacks
This Phase 3 trial tests whether starting anti-inflammatory treatment right away is better than waiting, using either azathioprine or rituximab, for children with anti-MOG antibody–related acute demyelinating episodes. It may help reduce future attacks and disability.
BesançonAges 6–17 - NCT05585814RecruitingPhase 2
New chemo plus immunotherapy before rectal surgery
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
ShanghaiAges 18–75 - NCT05264259Recruiting
Monoclonal antibodies for BK virus infection
This study tests a new treatment using lab-made antibodies to treat BK virus infection. It may help by controlling the virus in adults who already test BK positive.
StrasbourgAges 18 years+ - NCT05385432RecruitingPhase 3
Kidney transplant induction therapy for sensitized patients
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
ToursAges 18–79 - NCT05555888RecruitingPhase 2
Immunotherapy plus short-course radiation for early rectal cancer
This study tests whether combining immunotherapy with a short course of radiation given before surgery can improve outcomes in early-stage rectal cancer. It may help the immune system work better against the tumor before it is removed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04870437Recruiting
Light therapy study for kidney transplant rejection immune cells
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
BesançonAges 18 years+ - NCT04707872Recruiting
Study of a blood test after heart transplant
This study checks whether a special blood test can help detect heart transplant rejection or problems by comparing it to biopsy results. It may help your care team monitor your transplant with less guesswork.
Little Rock, ArkansasAges Any age - NCT04745949RecruitingPhase 2
Testing first-line antibody plus immunotherapy for mediastinal lymphoma
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Houston, TexasAges 18 years+ - NCT05045664RecruitingPhase 3
New follicular lymphoma treated with radiation plus antibody
This trial studies whether adding a targeted antibody to standard radiation can help people with early-stage, newly diagnosed follicular lymphoma. It aims to control the lymphoma more effectively while keeping treatment safe.
BerlinAges 18 years+ - NCT04365036RecruitingPhase 3
Check if PD-1 plus chemo-radiation helps early nasal lymphoma
This trial studies whether adding toripalimab (an immune therapy that targets PD-1) to standard chemo-radiation works better for newly diagnosed early-stage nasal natural killer/T-cell lymphoma. It’s designed to see if the combined treatment can improve outcomes while staying safe.
Guangzhou, GuangdongAges 18–75 - NCT04329065RecruitingPhase 2
Vaccine with targeted breast cancer drugs before surgery
This Phase 2 trial tests whether adding a cancer vaccine (with GM-CSF) to standard HER2-targeted chemotherapy before surgery improves treatment outcomes for HER2-positive breast cancer. If you join, you’ll receive planned medicine before surgery to treat the tumor, then continue with the study schedule.
Seattle, WashingtonAges 18 years+ - NCT04239703Recruiting
Kidney transplant biopsy study using blood test clues
This study looks at kidney transplant patients who are getting a kidney biopsy for usual clinical reasons. It tests whether special blood test results (from a sample taken as part of the study) can help spot transplant kidney problems earlier or more accurately.
Tampa, FloridaAges Any age - NCT06205602RecruitingPhase 2
HIV treatment with antibodies for a cure in Africa
This study tests if giving antibodies along with standard HIV medications can help control the virus without daily pills. It may lead to a functional cure for people living with HIV.
GaboroneAges 18–60 - NCT06767007RecruitingPhase 2
Radiation plus immunotherapy for recurrent rectal cancer
This trial studies a combination of SBRT (a precise kind of radiation) and an immunotherapy drug (PD-1 antibody) for people whose rectal cancer has come back in the pelvis and cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or stop it from growing.
Guangzhou, GuangdongAges 18–75 - NCT06323382Recruiting
Liver cancer: local therapy plus immunotherapy combo
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
Beijing, Beijing MunicipalityAges 18–80 - NCT07690787RecruitingPhase 2
Study of JS207 for nasopharyngeal cancer
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hong KongAges 18 years+ - NCT06241456RecruitingPhase 1
Experimental CAR-T cells targeting HER2 for advanced solid tumors
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT07407569RecruitingPhase 2
HPV vaccine study for women with HPV16
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
Antwerp, WilrijkAges 18–45 - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT06693440Recruiting
How PD-1 antibody therapy affects immune function in cancer
This trial is studying how PD-1 antibody therapy (a type of immunotherapy that helps your immune system fight cancer) affects the immune system in people with various cancers. It may be a good fit if you have a confirmed cancer diagnosis and have your medical records and immune test results available.
Zhengzhou, HenanAges 18 years+ - NCT05204862RecruitingPhase 1/Phase 2
TU2218 drug with PD-1 therapy for advanced solid tumors
This Phase 1/2 study tests TU2218 by itself and with PD-1–type immunotherapy (anti–PD-(L)1) in people with advanced solid cancers. It’s designed to find a safe dose and see whether the treatment can shrink tumors when standard options have not worked.
San Antonio, TexasAges 18 years+ - NCT05849740RecruitingPhase 4
CD38 antibody plus steroid for acquired hemophilia A
This trial studies whether a CD38-targeting antibody together with corticosteroids can improve outcomes in acquired hemophilia A. It is an “exploratory” Phase 4 study, meaning the goal is to learn more about safety and effectiveness in real-world patients.
TianjinAges 18 years+ - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+ - NCT03736889RecruitingPhase 2
Tislelizumab for MSI-H or dMMR solid tumors after prior treatment
This trial studies tislelizumab, an immune treatment that blocks PD-1, in people with MSI-H or dMMR solid tumors that cannot be fully removed or have spread, after other treatment has already been tried. It may help your immune system recognize and fight the cancer.
Hefei, AnhuiAges 18 years+
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 538 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.